[go: up one dir, main page]

AU2157000A - Ribavirin-pegylated interferon alfa induction hcv combination therapy - Google Patents

Ribavirin-pegylated interferon alfa induction hcv combination therapy

Info

Publication number
AU2157000A
AU2157000A AU21570/00A AU2157000A AU2157000A AU 2157000 A AU2157000 A AU 2157000A AU 21570/00 A AU21570/00 A AU 21570/00A AU 2157000 A AU2157000 A AU 2157000A AU 2157000 A AU2157000 A AU 2157000A
Authority
AU
Australia
Prior art keywords
ribavirin
induction
combination therapy
interferon alfa
pegylated interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21570/00A
Inventor
Janice K. Albrecht
Paul W. Glue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2157000A publication Critical patent/AU2157000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU21570/00A 1998-12-18 1999-12-16 Ribavirin-pegylated interferon alfa induction hcv combination therapy Abandoned AU2157000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21587698A 1998-12-18 1998-12-18
US09215876 1998-12-18
PCT/US1999/027935 WO2000037110A2 (en) 1998-12-18 1999-12-16 Ribavirin-pegylated interferon alfa induction hcv combination therapy

Publications (1)

Publication Number Publication Date
AU2157000A true AU2157000A (en) 2000-07-12

Family

ID=22804768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21570/00A Abandoned AU2157000A (en) 1998-12-18 1999-12-16 Ribavirin-pegylated interferon alfa induction hcv combination therapy

Country Status (7)

Country Link
EP (1) EP1140143A2 (en)
JP (1) JP2003507322A (en)
AR (1) AR021876A1 (en)
AU (1) AU2157000A (en)
CA (1) CA2354536A1 (en)
PE (1) PE20001369A1 (en)
WO (1) WO2000037110A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
CA2413258C (en) * 2000-06-30 2012-01-03 Zymogenetics, Inc. Interferon-like protein zcyto21
KR100851861B1 (en) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 Treatment of hepatitis c with thymosin, interferon and ribavirin
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
DE60237791D1 (en) 2001-04-20 2010-11-04 Bristol Myers Squibb Co Zytokinproteinfamilie
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
KR20050109918A (en) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 Process for the production of 2'-branched nucleosides
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
RU2371195C2 (en) * 2003-08-13 2009-10-27 Говард Дж. Смит Энд Эссошиэйтс Пти Лтд Method of virus infection treatment
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
BRPI0515279A (en) 2004-09-14 2008-07-15 Pharmasset Inc preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ATE519503T1 (en) * 2007-09-14 2011-08-15 Schering Corp METHOD FOR TREATING PATIENTS WITH HEPATITIS C
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
WO2010117936A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
RS54368B1 (en) 2010-03-31 2016-04-28 Gilead Pharmasset Llc CRYSTAL (S) -ISOPROPYL 2 - ((((S) - ((((2R, 3R, 4R, 5R) -5- (2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1- (2H) -IL) - 4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-IL) METOXY) (PHENOXY) PHOSPHORYL) AMINO) PROPANOATE
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
UA116087C2 (en) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Methods for treating hcv
EA201490837A1 (en) 2011-10-21 2014-11-28 Эббви Инк. METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69810822T2 (en) * 1997-09-21 2003-11-20 Schering Corp., Kenilworth Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection
CA2331823A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Also Published As

Publication number Publication date
EP1140143A2 (en) 2001-10-10
WO2000037110A3 (en) 2000-09-14
JP2003507322A (en) 2003-02-25
PE20001369A1 (en) 2000-12-09
AR021876A1 (en) 2002-08-07
WO2000037110A2 (en) 2000-06-29
CA2354536A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
AU2157000A (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
MXPA03003456A (en) Ribavirin-pegylated interferon alfa hcv combination therapy.
AU3938099A (en) Portable induction heater
AU136256S (en) Microwave oven
IL126286A0 (en) Mutual induction correction
AU131414S (en) Electric cooker
GB9817495D0 (en) Microwave oven
ZA958634B (en) Cookware
EP0923192A4 (en) Induction motor
AU134735S (en) Microwave oven
AU2156900A (en) Ribavirin-interferon alfa induction hcv combination therapy
GB2330920B (en) Microwave oven
GB2331218B (en) Microwave oven
GB2330958B (en) Microwave oven
GB2326521B (en) Magnetron
EP1047099A4 (en) Magnetron
AU3156599A (en) Induction heating
GB2330508B (en) Microwave oven
GB9813110D0 (en) Induction furnace
EG21396A (en) Microwave oven
GB9802741D0 (en) Microwave oven
GB9808971D0 (en) Microwave oven
GB2330942B (en) Magnetron
GB2337324B (en) Cooker
GB2348747B (en) Cooking hobs

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase